v3.25.1
Segment Reporting - Summary of Significant Research and Development and General and Administrative Expense to CODM (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue $ 29 $ 17,584
Platform development and early-stage research expenses [Abstract]    
Depreciation and amortization 395 1,143
Total research and development expenses 13,588 13,343
General and administrative expense    
Total general and administrative expenses 8,553 8,428
Total operating expenses 22,141 21,771
Operating loss (22,112) (4,187)
Total other income 1,547 12,775
(Loss) income from operations (20,565) 8,588
Net (loss) income (20,565) 8,588
Operating Segments    
Revenue 29 17,584
Platform development and early-stage research expenses [Abstract]    
Employee-related costs (including share-based compensation) 5,300 5,380
Laboratory supplies and services 454 744
CMOs and outsourced research and development 56 228
Facility-related costs, laboratory equipment, and maintenance 728 810
Depreciation and amortization 340 891
Licensing fees and other research and development costs 506 847
Total research and development expenses 13,588 13,343
General and administrative expense    
Employee-related costs (including share-based compensation) 5,460 5,009
Consulting and professional services 1,536 1,467
Other operating expenses and all other costs 1,557 1,952
Total general and administrative expenses 8,553 8,428
Total operating expenses 22,141 21,771
Operating loss (22,112) (4,187)
Total other income 1,547 12,775
(Loss) income from operations (20,565) 8,588
Net (loss) income (20,565) 8,588
Operating Segments | PBGENE-HBV    
Direct research and development expenses by product candidate:    
External development costs 1,601 3,056
Operating Segments | PBGENE-DMD    
Direct research and development expenses by product candidate:    
External development costs 2,438 175
Operating Segments | PBGENE-3243    
Direct research and development expenses by product candidate:    
External development costs $ 2,165 $ 1,212